Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NYSE | Common Stock
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products.
Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism.
It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; and Tentarix Biotherapeutics, LP.
The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Oct 30, 24 | 3.00 Increased by +1.69% | 2.92 Increased by +2.74% |
| Jul 25, 24 | 2.65 Decreased by -8.93% | 2.57 Increased by +3.11% |
| Apr 26, 24 | 2.31 Decreased by -6.10% | 2.23 Increased by +3.59% |
| Feb 2, 24 | 2.79 Decreased by -22.50% | 2.77 Increased by +0.72% |
| Oct 27, 23 | 2.95 Decreased by -19.40% | 2.86 Increased by +3.15% |
| Jul 27, 23 | 2.91 Decreased by -13.65% | 2.81 Increased by +3.56% |
| Apr 27, 23 | 2.46 Decreased by -24.07% | 2.46 |
| Feb 9, 23 | 3.60 Increased by +8.76% | 3.56 Increased by +1.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 14.46 B Increased by +3.83% | 1.56 B Decreased by -12.20% | Increased by +10.80% Decreased by -15.44% |
| Jun 30, 24 | 14.46 B Increased by +4.31% | 1.37 B Decreased by -32.31% | Increased by +9.47% Decreased by -35.11% |
| Mar 31, 24 | 12.31 B Increased by +0.70% | 1.37 B Increased by +472.80% | Increased by +11.12% Increased by +468.85% |
| Dec 31, 23 | 14.30 B Decreased by -5.42% | 822.00 M Decreased by -66.76% | Increased by +5.75% Decreased by -64.86% |
| Sep 30, 23 | 13.93 B Decreased by -5.97% | 1.78 B Decreased by -54.98% | Increased by +12.77% Decreased by -52.11% |
| Jun 30, 23 | 13.87 B Decreased by -4.92% | 2.02 B Increased by +119.05% | Increased by +14.60% Increased by +130.39% |
| Mar 31, 23 | 12.22 B Decreased by -9.70% | 239.00 M Decreased by -94.68% | Increased by +1.96% Decreased by -94.11% |
| Dec 31, 22 | 15.12 B Increased by +1.58% | 2.47 B Decreased by -38.85% | Increased by +16.35% Decreased by -39.80% |